-Survey Shows High Awareness and Potential for Rapid Adoption-
Report is Available for Download at: www.lifesciadvisors.com/marketresearch
Project Scope We solicited 4,251 urologists in our proprietary Expert Network of physicians on their expected us of the PCA3 assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy. We received responses from 273 practicing urologists and present the results in this note.
Product Survey Results
Of the 273 practicing urologists that diagnose men who are at risk of prostate cancer who responded to our survey, 32% practice at an academic or major referral center and 68% practice in at a community center. We note, however, that responses to the survey are similar for the two types of practices and we have therefore combined the groups in most of our analysis. According to our survey, each urologists is referred a median of 25.0 (mean of 28.5) men monthly to test for suspected prostate cancer and performs a median of 10.0 (mean of 13.6) biopsies per month.
Awareness of the PCA3 assay is relatively high among responding urologists, with 34.7% reporting being very familiar, 57.9% being somewhat familiar, and only 7.7% not familiar. 64.7% reported being aware that FDA has approved the test and 35.7% report not being aware of the approval.
Half (49.6%) of the responders intend to test their patients with this assay, 47.4% report that they may use it, and only 4.1% do not expect to use the test as asked in question 7. As asked in question 9, 6.3% report that they do not intend to use the test. The factors that are expected to influence use are ranked: (1) utility, (2) ease of use, (3), cost, and (4) other.